E.g., 07/30/2021
E.g., 07/30/2021
Title Category Credit Event Date Price
AUA Live en español (2020) $0.00 ¡La AUA le entrega una experiencia de educación virtual mostrando lo mejor de la AUA!En junio, más de 4,000 participantes de todo el mundo asistieron a AUA Live, un evento de transmisión en vivo de dos días de duración que contó con más de 35 horas de programación educativa selecta, incluida una conferencia magistral del Dr.
Active Surveillance for Prostate Cancer (2019)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 Active surveillance is the recommended management for low-risk prostate cancer but is currently underutilized. This course includes five modules about active surveillance for prostate cancer, with a target audience of urologists, trainees and allied health professionals.
Addressing Disparities in Prostate Cancer Care Podcast (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Podcast: Part 1 (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Podcast: Part 2 (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
AUA Live (2020) $299.00 June 27 – 28, 2020The AUA brings you a virtual education experience featuring the best of AUA! This program will include two days of virtual programming across three different channels, providing more than 24 hours of education. Explore the program below.
Case-Based Discussion: BCR and mHSPC & M0 CRPC Podcast (2020)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC). 
Case-Based Discussion: Early M1 CRPC Management & Advanced M1 CRPC Podcast (2020)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC). 
Case-Based Discussion: Role of Genetic Testing in Advanced M1 CRPC & M1 CRPC Post-Docataxel Chemotherapy and End-of-Life Care Podcast (2020)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC). 
Common Dilemmas in Prostate Cancer Detection and Management Webcast (2020)
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Non-Physician Participation
$0.00 Course participants will:Optimally use PSA and other biomarkers to minimize unnecessary testing and biopsy when screening men who are at average risk for prostate cancer.Understand the principles of “risk-adapted” screening for men at elevated risk for prostate cancer based on race, family history, early in life PSA, polygenic risk scores, and specific genetic mutations (eg BRCA1/2).Understand the roles of MRI, high frequency ultrasound and novel transperineal approaches to improve prostate biopsy.
CPS Castration-Resistant Prostate Cancer Amendment (2018)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Member only benefit! AUA Guidelines provide a comprehensive and rigorous summary of evidence relating to a variety of disease conditions, providing an indispensable resource for urologic education. The Clinical Problem Solving (CPS) Protocols guideline-based Case Scenarios were designed to help maximize the impact of the guidelines. The goal of this Guideline is  to provide a rational basis for treatment of patients with CRPC, based on currently available published data.
Genetic Testing and Personalized Medicine in Prostate Cancer Podcast (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Genetic Testing in Prostate Cancer: Considerations for Urologists and Their Patients Webcast (2020)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00
Incorporating Genomic Testing For Prostate Cancer into Your Practice Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 There are multiple genomic tests currently available for men with localized prostate cancer. The outcomes of these tests may lead to different treatment decisions (active surveillance, surgery, radiation, etc) or impact the frequency of monitoring. The availability and marketing of genomic testing has outpaced a reflective, evidence based medicine approach to using these tests.
Integrating Care for Oncology Patients: Establishing a Multidisciplinary Oncology Clinic with Advanced Therapeutics Webcast (2020)
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Non-Physician Participation
$0.00 This course will provide the framework to create a multidisciplinary clinic for the treatment of urologic malignancies, with representation of urologists, medical oncologists and additional specialists working together in a team-based approach. The course will focus on integration of advanced therapeutics including immune-based therapy where applicable in a multidisciplinary setting.

Pages